Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free EFTR Stock Alerts

eFFECTOR Therapeutics (EFTR) Competitors

eFFECTOR Therapeutics logo
$0.0002 0.00 (0.00%)
As of 10/2/2026
Compare

EFTR vs. ADTX, CMRA, EVLO, CALA, and SMFL

Should you buy eFFECTOR Therapeutics stock or one of its competitors? eFFECTOR Therapeutics's main competitors and comparable companies include Aditxt (ADTX), Comera Life Sciences (CMRA), Evelo Biosciences (EVLO), Calithera Biosciences (CALA), and Smart for Life (SMFL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does eFFECTOR Therapeutics compare to Aditxt?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Aditxt (NASDAQ:ADTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
eFFECTOR Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

eFFECTOR Therapeutics has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. eFFECTOR Therapeutics' return on equity of 0.00% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Aditxt -360,152.50%-374.60%-105.93%

eFFECTOR Therapeutics has higher earnings, but lower revenue than Aditxt. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Aditxt$14.34K0.18-$41.71M-$100.79 thousandN/A

eFFECTOR Therapeutics has a beta of 2.73, suggesting that its share price is 173% more volatile than the broader market. Comparatively, Aditxt has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market.

In the previous week, Aditxt had 1 more articles in the media than eFFECTOR Therapeutics. MarketBeat recorded 1 mentions for Aditxt and 0 mentions for eFFECTOR Therapeutics. eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Aditxt'saverage media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Aditxt Neutral

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. Comparatively, 15.5% of Aditxt shares are held by institutional investors. 4.7% of eFFECTOR Therapeutics shares are held by insiders. Comparatively, 0.0% of Aditxt shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

eFFECTOR Therapeutics beats Aditxt on 8 of the 12 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Comera Life Sciences?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

eFFECTOR Therapeutics has a beta of 2.73, suggesting that its stock price is 173% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Comera Life Sciences has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Comera Life Sciences N/A N/A N/A

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Comera Life Sciences Neutral

Summary

Comera Life Sciences beats eFFECTOR Therapeutics on 4 of the 7 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Evelo Biosciences?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are held by institutional investors. 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Evelo Biosciences N/A N/A N/A

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Evelo Biosciences Neutral

eFFECTOR Therapeutics has a beta of 2.73, indicating that its stock price is 173% more volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

Summary

eFFECTOR Therapeutics beats Evelo Biosciences on 5 of the 6 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Calithera Biosciences?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Calithera Biosciences (NASDAQ:CALA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Comparatively, 6.6% of Calithera Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Calithera Biosciences N/A N/A N/A

In the previous week, Calithera Biosciences had 1 more articles in the media than eFFECTOR Therapeutics. MarketBeat recorded 1 mentions for Calithera Biosciences and 0 mentions for eFFECTOR Therapeutics. eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Calithera Biosciences Neutral

eFFECTOR Therapeutics has a beta of 2.73, indicating that its stock price is 173% more volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.51, indicating that its stock price is 251% less volatile than the broader market.

Summary

eFFECTOR Therapeutics beats Calithera Biosciences on 4 of the 6 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Smart for Life?

Smart for Life (NASDAQ:SMFL) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
eFFECTOR Therapeutics Neutral

Smart for Life has a beta of 17.51, indicating that its stock price is 1,651% more volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.73, indicating that its stock price is 173% more volatile than the broader market.

28.4% of Smart for Life shares are owned by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by company insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Smart for Life has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

Summary

Smart for Life beats eFFECTOR Therapeutics on 5 of the 7 factors compared between the two stocks.

Get eFFECTOR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EFTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EFTR vs. The Competition

Export
MetriceFFECTOR TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1K$12.28B$7.15B$13.28B
Dividend YieldN/A2.65%2.54%17.33%
P/E Ratio0.00802.26274.7126.04
Price / SalesN/A940.01656.46105.13
Price / CashN/A86.6678.8752.62
Price / Book0.0010.5210.936.31
Net Income-$35.81M$2.86B$3.51B$362.16M
7 Day PerformanceN/A-1.58%-2.00%-1.66%
1 Month PerformanceN/A-5.55%-6.19%-4.68%
1 Year PerformanceN/A-2.19%8.03%1.57%

eFFECTOR Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EFTR
eFFECTOR Therapeutics
N/A$0.00
flat		N/AN/A$1KN/AN/A14
ADTX
Aditxt
0.0262 of 5 stars		$0.00
+2.2%		N/A-100.0%$4K$14.34KN/A60
CMRA
Comera Life Sciences
N/A$0.00
flat		N/AN/A$3K$1.00MN/A2
EVLO
Evelo Biosciences
N/AN/AN/AN/A$2KN/AN/A66
CALA
Calithera Biosciences
N/A$0.00
flat		N/A+0.0%$1KN/AN/A60

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EFTR) was last updated on 10/4/2026 by MarketBeat.com Staff.
From Our Partners
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...
American Hartford Gold | Sponsoredtc pixel
WATCH THIS BEFORE DECEMBER 8th!!
James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...
Paradigm Press | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
How Elon’s Empire Ends (and how to profit)
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...
Chaikin Analytics | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
I'm giving you a space stock today. Free.
On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...
Behind the Markets | Sponsoredtc pixel
A new kind of civil war is coming after election day?
Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...
Stansberry Research | Sponsoredtc pixel